Fresenius Medical Care stock reacts to fresh analyst downgrades
Published on 09/16/2026 at 14:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius Medical Care AG & Co. KGaA (ISIN DE0005785802) stock has come under renewed scrutiny after analysts at JP Morgan reiterated an Underweight rating on September 9, 2026, keeping the shares below the sector’s top picks.
Analyst sentiment turns more cautious
According to finanzen.net on September 16, 2026, JP Morgan Chase & Co. confirmed its Underweight stance on Fresenius Medical Care on September 9, 2026, while Jefferies stayed at Underperform and DZ Bank maintained a Buy recommendation from early August 2026.
The mixed analyst picture means investors face both downside risk and selective support, with JP Morgan’s Underweight contrasting with DZ Bank’s Buy rating from August 6, 2026, as reported by finanzen.net.
Recent price performance and market context
Per data cited by finanzen.net on September 16, 2026, Fresenius Medical Care shares on Xetra were trading around the mid-30-euro range, reflecting a modest pullback after a short sequence of gains in recent sessions.
A separate indicator snapshot from boerse-social.com on September 16, 2026 shows Fresenius Medical Care stock had gained a cumulative 3.01 percent over the preceding three trading days, with individual moves of 0.56 percent, 2.91 percent and a slight decline of 0.13 percent, indicating short-term volatility around a broadly sideways trend.
Balance sheet and operating metrics
From a balance-sheet perspective, Fresenius Medical Care reported a current ratio of 0.76 for 2026, meaning current assets cover 76 percent of short-term liabilities, according to figures compiled by Eulerpool as of 2026.
While the latest quarterly revenue and earnings figures are not highlighted in the recent week’s coverage, past results have shown the group working to improve profitability and cash generation after prior years of margin pressure, a process that remains central to how analysts such as JP Morgan and Jefferies frame their cautious ratings noted by finanzen.net.
Stock price snapshot and investor takeaways
As of September 15, 2026, the most recent completed Xetra session, Fresenius Medical Care stock closed near EUR 39.78, based on an indication cited by boerse-social.com, with an intraday indication of EUR 39.67 to EUR 39.69 on September 16, 2026 showing a slight decline of 0.25 percent from that latest closing level.
Fresenius Medical Care stock facts
- Company: Fresenius Medical Care AG & Co. KGaA
- ISIN: DE0005785802
- Ticker: FME
- Trading venue: Xetra
- Price (as of September 15, 2026): 39.78 EUR
- Sector / Industry: Health Care / Medical Equipment
- Index membership: DAX
